JP2020514311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514311A5 JP2020514311A5 JP2019539223A JP2019539223A JP2020514311A5 JP 2020514311 A5 JP2020514311 A5 JP 2020514311A5 JP 2019539223 A JP2019539223 A JP 2019539223A JP 2019539223 A JP2019539223 A JP 2019539223A JP 2020514311 A5 JP2020514311 A5 JP 2020514311A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutically acceptable
- compound
- acceptable salt
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 31
- 229960003852 atezolizumab Drugs 0.000 claims description 25
- 229940125904 compound 1 Drugs 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 11
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 208000037843 metastatic solid tumor Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000000405 serological effect Effects 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 235000004443 Ricinus communis Nutrition 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 claims 2
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 238000001802 infusion Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022104523A JP2022121594A (ja) | 2017-01-20 | 2022-06-29 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
| JP2023222710A JP2024019720A (ja) | 2017-01-20 | 2023-12-28 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448869P | 2017-01-20 | 2017-01-20 | |
| US62/448,869 | 2017-01-20 | ||
| US201762458447P | 2017-02-13 | 2017-02-13 | |
| US62/458,447 | 2017-02-13 | ||
| PCT/US2018/014523 WO2018136796A1 (en) | 2017-01-20 | 2018-01-19 | Combinations of cabozantinib and atezolizumab to treat cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104523A Division JP2022121594A (ja) | 2017-01-20 | 2022-06-29 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514311A JP2020514311A (ja) | 2020-05-21 |
| JP2020514311A5 true JP2020514311A5 (enExample) | 2021-02-25 |
| JP7222895B2 JP7222895B2 (ja) | 2023-02-15 |
Family
ID=61569414
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539223A Active JP7222895B2 (ja) | 2017-01-20 | 2018-01-19 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
| JP2022104523A Pending JP2022121594A (ja) | 2017-01-20 | 2022-06-29 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
| JP2023222710A Pending JP2024019720A (ja) | 2017-01-20 | 2023-12-28 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104523A Pending JP2022121594A (ja) | 2017-01-20 | 2022-06-29 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
| JP2023222710A Pending JP2024019720A (ja) | 2017-01-20 | 2023-12-28 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11198731B2 (enExample) |
| EP (1) | EP3570840B1 (enExample) |
| JP (3) | JP7222895B2 (enExample) |
| KR (2) | KR20230169458A (enExample) |
| CN (4) | CN110352057A (enExample) |
| AU (2) | AU2018210397B2 (enExample) |
| BR (1) | BR112019015011A2 (enExample) |
| ES (1) | ES3031468T3 (enExample) |
| IL (1) | IL268138B (enExample) |
| MA (1) | MA47310A (enExample) |
| MX (2) | MX389966B (enExample) |
| UA (1) | UA126970C2 (enExample) |
| WO (1) | WO2018136796A1 (enExample) |
| ZA (1) | ZA201904652B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
| US11141413B2 (en) | 2016-04-15 | 2021-10-12 | Exelixis, Inc. | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| UA126970C2 (uk) | 2017-01-20 | 2023-03-01 | Екселіксіс, Інк. | Комбінації кабозантинібу і атезолізумабу для лікування раку |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| HRP20251184T1 (hr) | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| TWI787523B (zh) | 2018-06-15 | 2022-12-21 | 漢達生技醫藥股份有限公司 | 達沙替尼十二烷基硫酸鹽之結晶 |
| BR112021004126A2 (pt) * | 2018-09-05 | 2021-05-25 | Ventria Bioscience Inc. | formulação profilática e/ou terapêutica estabilizada e método profilático ou terapêutico |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| TWI923583B (zh) * | 2020-04-14 | 2026-05-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物 |
| PH12023550160A1 (en) * | 2020-07-31 | 2023-09-18 | Exelixis Inc | Combinations for the Treatment of Cancer |
| US20230314440A1 (en) * | 2020-08-21 | 2023-10-05 | Exelixis, Inc. | Method of treating cancer |
| CA3212604A1 (en) * | 2021-03-19 | 2022-09-22 | Merck Sharp & Dohme Llc | Methods for treating cancer with anti-ilt3 antibodies |
| US11620580B2 (en) * | 2021-04-01 | 2023-04-04 | Banjo Health Inc. | Methods and systems for probabilistic filtering of candidate intervention representations |
| KR20250136810A (ko) | 2023-01-31 | 2025-09-16 | 한다 온콜로지, 엘엘씨 | 개선된 카보잔티닙 조성물 및 사용 방법 |
| KR102966277B1 (ko) * | 2024-04-25 | 2026-05-18 | 한국 한의학 연구원 | 카보잔티닙을 유효성분으로 함유하는 항암제 내성암의 예방 또는 치료용 약학 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| TW201920110A (zh) | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
| WO2012009722A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| EP2983639A1 (en) * | 2013-04-04 | 2016-02-17 | Exelixis, Inc. | Drug combinations to treat cancer |
| EA032757B1 (ru) * | 2014-02-14 | 2019-07-31 | Экселиксис, Инк. | Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения |
| US11141413B2 (en) * | 2016-04-15 | 2021-10-12 | Exelixis, Inc. | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
| MA44733A (fr) | 2016-04-19 | 2019-02-27 | Exelixis Inc | Procédé de traitement du cancer du sein négatif triple |
| UA126970C2 (uk) * | 2017-01-20 | 2023-03-01 | Екселіксіс, Інк. | Комбінації кабозантинібу і атезолізумабу для лікування раку |
-
2018
- 2018-01-19 UA UAA201909420A patent/UA126970C2/uk unknown
- 2018-01-19 MA MA047310A patent/MA47310A/fr unknown
- 2018-01-19 US US16/479,143 patent/US11198731B2/en active Active
- 2018-01-19 EP EP18709192.1A patent/EP3570840B1/en active Active
- 2018-01-19 MX MX2019008032A patent/MX389966B/es unknown
- 2018-01-19 AU AU2018210397A patent/AU2018210397B2/en active Active
- 2018-01-19 ES ES18709192T patent/ES3031468T3/es active Active
- 2018-01-19 WO PCT/US2018/014523 patent/WO2018136796A1/en not_active Ceased
- 2018-01-19 JP JP2019539223A patent/JP7222895B2/ja active Active
- 2018-01-19 BR BR112019015011A patent/BR112019015011A2/pt not_active Application Discontinuation
- 2018-01-19 CN CN201880013200.7A patent/CN110352057A/zh not_active Withdrawn
- 2018-01-19 KR KR1020237041680A patent/KR20230169458A/ko not_active Ceased
- 2018-01-19 CN CN202311144073.3A patent/CN117205312A/zh active Pending
- 2018-01-19 CN CN202311144084.1A patent/CN117771363A/zh active Pending
- 2018-01-19 KR KR1020197024015A patent/KR102610764B1/ko active Active
- 2018-01-19 IL IL268138A patent/IL268138B/en unknown
- 2018-01-19 CN CN202311144074.8A patent/CN117205313A/zh active Pending
-
2019
- 2019-07-03 MX MX2022001718A patent/MX2022001718A/es unknown
- 2019-07-16 ZA ZA2019/04652A patent/ZA201904652B/en unknown
-
2021
- 2021-11-04 US US17/519,327 patent/US20220056138A1/en not_active Abandoned
-
2022
- 2022-06-29 JP JP2022104523A patent/JP2022121594A/ja active Pending
-
2023
- 2023-12-28 JP JP2023222710A patent/JP2024019720A/ja active Pending
-
2024
- 2024-05-24 AU AU2024203472A patent/AU2024203472A1/en not_active Abandoned